Tissue-specific mRNA expression profiles of human solute carrier 35 transporters

Drug Metabolism and Pharmacokinetics

Volumn 24, Issue 1, 2009, Pages 91-99

  Nishimura, Masuhiro ^a   Suzuki, Satoshi ^b   Satoh, Tetsuo ^b   Naito, Shinsaku ^a  

^a OTSUKA PHARMACEUTICAL CO LTD   (Japan)

^b BUILDING RESEARCH INSTITUTE   (Japan)

Author keywords

Human; MRNA expression; Quantification; SLC35 transporter; Tissue distribution

Indexed keywords

CARRIER PROTEIN; MESSENGER RNA; SOLUTE CARRIER 35 TRANSPORTER; UNCLASSIFIED DRUG;

ADIPOSE TISSUE; ADRENAL GLAND; ADULT; ARTICLE; BLADDER; BONE MARROW; BRAIN TISSUE; BREAST; CARCINOMA CELL; CELL STRAIN HEPG2; CEREBELLUM; COLON; CONTROLLED STUDY; FETUS; FETUS (ANATOMY); GENE EXPRESSION PROFILING; HEART; HELA CELL; HUMAN; HUMAN TISSUE; KIDNEY PARENCHYMA; LEUKOCYTE; LUNG PARENCHYMA; NUCLEOTIDE SEQUENCE; OVARY; PANCREAS; PLACENTA; PROSTATE; REAL TIME POLYMERASE CHAIN REACTION; RETINA; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SALIVARY GLAND; SKELETAL MUSCLE; SMALL INTESTINE; SMOOTH MUSCLE; SPINAL CORD; SPLEEN; STOMACH; TESTIS; THYMUS; THYROID GLAND; TISSUE SPECIFICITY; TONSIL; TRACHEA; UTERUS;

EID: 67649386565     PISSN: 13474367     EISSN: 18800920     Source Type: Journal    
DOI: 10.2133/dmpk.24.91     Document Type: Article

References (20)

1. Ishida, N. and Kawakita, M.: Molecular physiology and pathology of the nucleotide sugar transporter family (SLC35). Pflugers. Arch., 447: 768-775 (2004).
2. Sarangi, A., Bupp, K. and Roth, M. J.: Identification of a retroviral receptor used by an envelope protein derived by peptide library screening. Proc. Natl. Acad. Sci. USA, 104: 11032-11037 (2007).
3. Kamiyama, S., Sasaki, N., Goda, E., Ui-Tei, K., Saigo, K., Narimatsu, H., Jigami, Y., Kannagi, R., Irimura, T. and Nishihara, S.: Molecular cloning and characterization of a novel 3′ -phosphoadenosine 5′-phosphosulfate transporter, PAPST2. J. Biol. Chem., 281: 10945-10953 (2006).
4. Muraoka, M., Kawakita, M. and Ishida, N.: Molecular characterization of human UDP-glucuronic acid/UDP-N-acetylgalactosamine transporter, a novel nucleotide sugar transporter with dual substrate specificity. FEBS Lett., 495: 87-93 (2001).
5. Matsuyama, R., Togo, S., Shimizu, D., Momiyama, N., Ishikawa, T., Ichikawa, Y., Endo, I., Kunisaki, C., Suzuki, H., Hayasizaki, Y. and Shimada, H.: Predicting 5-fluorouracil chemosensitivity of liver metastases from colorectal cancer using primary tumor specimens: three-gene expression model predicts clinical response. Int. J. Cancer, 119: 406-413 (2006).
6. Finel, M. and Kurkela, M.: The UDP-glucuronosyltransferases as oligomeric enzymes. Curr. Drug Metab., 9: 70-76 (2008).
7. Nishimura, M., Naito, S. and Yokoi, T.: Tissue-specific mRNA expression profiles of human nuclear receptor subfamilies. Drug Metab. Pharmacokinet., 19: 135-149 (2004).
8. Nishimura, M., Yamaguchi, M., Yamauchi, A., Ueda, N. and Naito, S.: Role of soybean oil fat emulsion in the prevention of hepatic xenobiotic transporter mRNA up- and down-regulation induced by overdose of fat-free total parenteral nutrition in infant rats. Drug Metab. Pharmacokinet., 20: 46-54 (2005).
9. Nishimura, M. and Naito, S.: Tissue-specific mRNA expression profiles of human ATP-binding cassette and solute carrier transporter superfamilies. Drug Metab. Pharmacokinet., 20: 452-477 (2005).
10. Nishimura, M. and Naito, S.: Tissue-specific mRNA expression profiles of human toll-like receptors and related genes. Biol. Pharm. Bull., 28: 886-892 (2005).
11. Nishimura, M. and Naito, S.: Tissue-specific mRNA expression profiles of human phase I metabolizing enzymes except for cytochrome P450 and phase II metabolizing enzymes. Drug Metab. Pharmacokinet., 21: 357-374 (2006).
12. Yamaguchi, M., Yamauchi, A., Nishimura, M., Ueda, N. and Naito, S.: Soybean oil fat emulsion prevents cytochrome P450 mRNA down-regulation induced by fat-free overdose total parenteral nutrition in infant rats. Biol. Pharm. Bull., 28: 143-147 (2005).
13. Nishimura, M. and Naito, S.: Tissue-specific mRNA expression profiles of human solute carrier transporter superfamilies. Drug Metab. Pharmacokinet., 23: 22-44 (2008).
14. Ishida, N., Yoshioka, S., Chiba, Y., Takeuchi, M. and Kawakita, M.: Molecular cloning and functional expression of the human Golgi UDP-N-acetylglucosamine transporter. J. Biochem., 126: 68-77 (1999).
15. Leach, R. E., Duniec-Dmuchowski, Z. M., Pesole, G., Tanaka, T. S., Ko, M. S., Armant, D. R. and Krawetz, S. A.: Identification, molecular characterization, and tissue expression of OVCOV1. Mamm. Genome, 13: 619-624 (2002).
16. Ishida, N., Kuba, T., Aoki, K., Miyatake, S., Kawakita, M. and Sanai, Y.: Identification and characterization of human Golgi nucleotide sugar transporter SLC35D2, a novel member of the SLC35 nucleotide sugar transporter family. Genomics, 85: 106-116 (2005).
17. Kumamoto, K., Goto, Y., Sekikawa, K., Takenoshita, S., Ishida, N., Kawakita, M. and Kannagi, R.: Increased expression of UDP-galactose transporter messenger RNA in human colon cancer tissues and its implication in synthesis of Thomsen-Friedenreich antigen and sialyl Lewis A/X determinants. Cancer Res., 61: 4620-4627 (2001).
18. Luhn, K., Wild, M. K., Eckhardt, M., Gerardy-Schahn, R. and Vestweber, D.: The gene defective in leukocyte adhesion deficiency II encodes a putative GDP-fucose transporter. Nat. Genet., 28: 69-72 (2001).
19. Lubke, T., Marquardt, T., Etzioni, A., Hartmann, E., von Figura, K. and Korner, C.: Complementation cloning identifies CDGIIc, a new type of congenital disorders of glycosylation, as a GDP-fucose transporter deficiency. Nat. Genet., 28: 73-76 (2001).
20. Martinez-Duncker, I., Dupre, T., Piller, V., Piller, F., Candelier, J. J., Trichet, C., Tchernia, G., Oriol, R. and Mollicone, R.: Genetic complementation reveals a novel human congenital disorder of glycosylation of type II, due to inactivation of the Golgi CMP-sialic acid transporter. Blood, 105: 2671-2676 (2005).